J&J says court finds Remicade patent invalid

Reuters Health Information: J&J says court finds Remicade patent invalid

J&J says court finds Remicade patent invalid

Last Updated: 2016-08-18

By Reuters Staff

(Reuters) - Johnson & Johnson said a U.S. court had held its patent for autoimmune drug Remicade (infliximab) invalid, ruling in favor of two companies seeking to bring a cheaper version of the blockbuster drug to market.

Remicade, J&J's biggest product, had $6.6 billion in sales last year. The drug's patent will lapse in September 2018.

In March 2015, J&J filed a lawsuit against Celltrion Inc and Pfizer Inc-owned Hospira seeking a declaratory judgment that their biosimilar product infringes several of its patents.

Celltrion and Hospira's biosimilar, Inflectra, received U.S. regulatory approval in April.

Biosimilars are lower-cost copies of complex biotech drugs.

J&J, which is also defending other Remicade patents, said it plans to appeal the latest court decision.

"Assuming biosimilar competition, we think Remicade revenues will decline by just over $1 billion in 2017, costing J&J close to $0.20 in EPS," J.P. Morgan analysts wrote in a client note.

© Copyright 2013-2018 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.